Opinion

Video

Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC

Expert urologist explores potential treatments for BCG-unresponsive intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC), including immune checkpoint inhibitors, oncolytic viral therapy, cytokine agonists, immunomodulators, and the recently approved drugs pembrolizumab and nogapendekin alfa inbakicept-pmln.

  1. Can you discuss some of the exploratory treatments for BCG‐unresponsive intermediate and high risk‐NMIBC? (eg. immune checkpoint inhibitors (ICI), oncolytic viral therapy, cytokine agonists, and other immunomodulators)
  2. BCG‐unresponsiveness (definition?)
    1. Include (recently) approved immunotherapies: pembrolizumab, nogapendekin alfa inbakicept-pmln
  3. Gene therapy: nadofaragene firadenovec
Related Videos
Oliver Sartor, MD, is featured in this series.
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Oliver Sartor, MD, is featured in this series.
Related Content
QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC
November 19th 2024

QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC

Hannah Clarke
At the time of data cutoff, 71% of patients achieved a complete response following treatment.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Phase 3 ENLIGHTED trial: Padeliporfin VTP shows promise in low-grade UTUC
November 7th 2024

Phase 3 ENLIGHTED trial: Padeliporfin VTP shows promise in low-grade UTUC

Hannah Clarke
At the end of the induction phase, 86% of patients had achieved a complete response.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Study to assess performance of CxBladder test in urothelial carcinoma surveillance
November 6th 2024

Study to assess performance of CxBladder test in urothelial carcinoma surveillance

Hannah Clarke
The observational LOBSTER study has already enrolled 303 patients and collected 479 samples.
TYRA-300 shows encouraging safety, efficacy in FGFR3+ metastatic urothelial carcinoma
October 31st 2024

TYRA-300 shows encouraging safety, efficacy in FGFR3+ metastatic urothelial carcinoma

Hannah Clarke
Anti-tumor activity was observed across all patients with FGFR3-altered metastatic urothelial carcinoma who were treated at the dose levels of 90 mg and higher.
© 2024 MJH Life Sciences

All rights reserved.